In the massive litigation over alleged side effects from the diabetes drug Avandia, a federal judge has issued a pair of opinions that reject efforts by the drug’s maker, GlaxoSmithKline, to significantly limit the scope of the case.

But GSK also secured some important wins when, in six separate opinions, the same judge dismissed proposed class action suits by former users of the drug who have suffered no side effects but who sought medical monitoring and demanded refunds under state consumer protection law.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]